BlephEx-treatment for blepharitis: a prospective randomized placebo-controlled trial.

Area of Science:

• Ophthalmology
• Medical Devices
• Clinical Trials

Background:

• Blepharitis is a common chronic eyelid inflammation with limited treatment options.
• The BlephEx™ device offers automated eyelid debridement to address blepharitis.
• Existing evidence for BlephEx™ efficacy is limited.

Purpose of the Study:

• To evaluate the efficacy of BlephEx™ treatment for symptomatic blepharitis.
• To compare BlephEx™ therapy against a sham treatment in a randomized controlled trial.

Main Methods:

• A double-masked randomized controlled trial involving 42 patients with refractory blepharitis.
• Outcome measures included Ocular Surface Disease Index (OSDI), tear break-up time (TBUT), Schirmer test, and Efron grading.
• A crossover design was employed, with groups swapping treatments after 4 weeks.

Main Results:

• The sham treatment group showed a significant decrease in Efron grading scores.
• No statistically significant differences were found in OSDI, TBUT, or Schirmer test results between groups.
• BlephEx™ showed non-significant trends towards improvement in OSDI and Efron scores, and TBUT.

Conclusions:

• BlephEx™ therapy did not demonstrate significant outcome differences compared to sham treatment for blepharitis.
• The study does not support the recommendation of BlephEx™ for treating blepharitis.
• Mild discomfort was the primary side effect, occurring equally in both groups.